Mod GRF 1-29: Importing to Argentina

Mod GRF (1-29) can be imported to Argentina. PeptoClinic quotes and ships this research peptide to Argentine destinations as laboratory reference material, with customs documentation prepared for that classification. The compound enters the country, but not as a medicine: it enters as a research input.

What Mod GRF (1-29) is, and why it goes by two names

Mod GRF (1-29) — short for Modified GRF 1-29 — is a synthetic analogue of growth hormone-releasing hormone (GHRH). The native peptide degrades rapidly in solution; the modified version incorporates four amino acid substitutions that extend its stability. In English-language technical literature, the compound also appears as CJC-1295 without DAC (*without drug affinity complex*), the commercial name established by the first large-scale synthesiser. Both names refer to the same molecule.

In PeptoClinic's catalogue, the compound is listed as CJC-1295 without DAC. Researchers sourcing this material for Argentine programmes should start at the CJC-1295 without DAC — Argentina page, which has the specific logistics and documentation detail for Argentine imports.

Published research on the compound — searchable through PubMed — covers primarily in vitro work on somatotropic axis physiology and GH secretion. PeptoClinic does not provide interpretation of that literature or guidance on applications.

How Argentina regulates this compound

ANMAT regulates medicines, biologics, medical devices, and cosmetics in Argentina. Compounds classified as laboratory reference material — no therapeutic indication, no sanitary registration number, intended exclusively for research — do not enter as medicines and are not subject to the pharmaceutical control regime ANMAT applies to registered products.

The relevant customs classification is research reagent or analytical reference material. Under that classification, what the file requires is compound identity supported by laboratory analysis, lot traceability, a declaration of in vitro research use, and a safety data sheet for the material.

What complicates or blocks entry is material presented with therapeutic indications, package inserts, or dosing references. That converts the compound, in regulatory terms, into an unregistered medicine, and the resulting control regime is significantly more demanding.

PeptoClinic prepares the documentation for each shipment to Argentina under the laboratory reference material classification and reviews the file individually before quoting, because quantity, the receiving laboratory, and the exact lot composition can all affect how customs handles the import.

What documentation ships with each lot

Every shipment to Argentina includes:

• Certificate of Analysis (COA) issued by the independent analytical laboratory that ran the analysis, with compound identity, HPLC purity result, task number, and lot number.
• Safety Data Sheet (SDS) for the material, in the format required for laboratory inputs.
• Declaration of use: the material is supplied exclusively for in vitro and laboratory research, with no indication for administration to humans or animals.
• Supporting documentation for the Argentine customs file, prepared under the reference material framework.

The analytical laboratory that signs the lot reports for PeptoClinic is Janoshik Analytical. Every certificate includes the task number with which the result can be verified directly on the laboratory's website. Published reports for the analysed lots are listed on the Quality page.

The minimum purity PeptoClinic specifies for its research peptides is ≥99% by HPLC. The lowest figure published in Janoshik certificates for analysed lots in the line is 99.669%. The highest published result is not cited here because the floor is the figure a buyer can demand as a minimum; the best result varies by lot.

Why the customs declaration determines the outcome

A common failure in research peptide imports is arriving with a generic declaration — no classification that distinguishes research input from consumer product. That creates ambiguity at customs, because the officer must interpret the material without documentation that frames it.

When a compound enters as a research reagent with COA, SDS, and declaration of use, the classification is more straightforward. There is no safety evaluation for consumption because the material is not destined for consumption; what matters is identity and purity as a reference compound.

A second frequent problem is a mismatch between the package and its documentation: a correctly named compound presented in packaging that carries clinical use information can fall into the same regime as an unregistered medicine. PeptoClinic ships the material without use instructions on the primary container, consistent with the research classification.

The final customs determination is the importer's responsibility, but PeptoClinic does not ship until the documentation is complete, and can support the importer with written backup during any customs query.

How to request a quote for Mod GRF (1-29) to Argentina

There are no published prices and no online stock. The process is a technical consultation: describe the compound, the quantity the programme requires, the purity specification, and the Argentine destination. PeptoClinic reviews the available lot against its documentation and returns a written quote, normally within one business day. The quote includes the material cost, Argentine logistics, and the import documents.

To open a consultation, write to [email protected] or go directly to the CJC-1295 without DAC — Argentina page.

If the programme also requires other peptides — Ipamorelin, for example, for a comparative in vitro study on GH secretagogues — those can be included in the same consultation. PeptoClinic quotes combined shipments under a single customs file.

For laboratory research only

Mod GRF (1-29) is a research peptide. PeptoClinic supplies this material exclusively for in vitro and laboratory research use. It is not approved or intended for administration to humans or animals.

This compound has not been evaluated by ANMAT, the FDA, or any equivalent authority as a medicine, supplement, or consumer product. PeptoClinic is not a pharmacy, a clinic, or a healthcare provider. No prescription is written, no clinical guidance is offered, and requests for human administration protocols are declined.

Compliance with applicable regulations on the import and use of research material is the responsibility of the recipient and their institution.